Intercept Pharmaceuticals | ICPT - Des Atouts



Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amarin USD 659.81M 10.31M 2025-09
Amgen USD 90.59B 445M 2025-12
Arrowhead Research USD 1.6B 218.89M 2025-12
AstraZeneca USD 114.07B 382M 2025-12
Biogen USD 29.44B 232M 2025-12
Bristol-Myers Squibb USD 96.89B 2.21B 2025-09
Eli Lilly USD 112.48B 2.46B 2025-12
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Esperion Therapeutics USD 364.02M 16.93M 2025-09
Galectin Therapeutics USD 27.65M 1.76M 2024-06
Gilead Sciences USD 59.02B 490M 2025-12
GlaxoSmithKline GBP 61.12B 221M 2025-12
Incyte USD 6.96B 627.62M 2025-12
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
Moderna USD 12.34B 203M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novartis USD 107.29B 2.89B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Regeneron Pharmaceuticals USD 40.56B 389.3M 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12